At the time of writing, Kyverna Therapeutics Inc [KYTX] stock is trading at $5.11, up 16.40%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KYTX shares have gain 16.00% over the last week, with a monthly amount drifted -0.20%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Kyverna Therapeutics Inc [NASDAQ: KYTX] stock has seen the most recent analyst activity on October 10, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $13. Previously, Rodman & Renshaw started tracking the stock with Buy rating on October 09, 2024, and set its price target to $16. On July 03, 2024, H.C. Wainwright initiated with a Neutral rating and assigned a price target of $8 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $44 on March 04, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $40 as its price target on March 04, 2024. Leerink Partners started tracking with a Outperform rating for this stock on March 04, 2024, and assigned it a price target of $48. In a note dated March 04, 2024, JP Morgan initiated an Overweight rating and provided a target price of $39 on this stock.
For the past year, the stock price of Kyverna Therapeutics Inc fluctuated between $3.92 and $35.06. Kyverna Therapeutics Inc [NASDAQ: KYTX] shares were valued at $5.11 at the most recent close of the market.
Analyzing the KYTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.51 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.64 points at the first support level, and at 4.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.41, and for the 2nd resistance point, it is at 5.70.
Ratios To Look Out For
It is important to note that Kyverna Therapeutics Inc [NASDAQ:KYTX] has a current ratio of 10.50. As well, the Quick Ratio is 10.50, while the Cash Ratio is 3.38.
Transactions by insiders
Recent insider trading involved Vida Ventures, LLC, 10% Owner, that happened on Feb 12 ’24 when 0.25 million shares were purchased. 10% Owner, Bain Capital Life Sciences Inv completed a deal on Feb 12 ’24 to buy 0.45 million shares. Meanwhile, 10% Owner GILEAD SCIENCES, INC. bought 0.91 million shares on Feb 12 ’24.
